Pharmaceutical - Immunologicals, Respiratory and Pulmonary

Filter

Popular Filters

Stallergenes and DBV Technologies collaborate in birch pollen allergy research

18-10-2013

French allergy specialists Stallergenes and DBV Technologies, creator of Viaskin for the treatment of…

DBV TechnologiesImmunologicalsPharmaceuticalResearchRespiratory and PulmonaryStallergenes

Positive Ph III findings on ALK's new house dust mite allergy immunotherapy; EU filing expected in 2014

20-06-2013

Denmark-based allergy specialist ALK Abello (ALKB: DC) has announced positive outcome of the first of…

ALK AbelloImmunologicalsPharmaceuticalRegulationResearchRespiratory and Pulmonary

US FDA accepts Merck & Co's BLA for Timothy grass pollen allergy product

27-03-2013

US pharma giant Merck & Co (NYSE: MRK) says that its Biologics License Application for the investigational…

ALK AbelloGrazaxImmunologicalsMerck & CoPharmaceuticalRegulationRespiratory and Pulmonary

Positive NICE news for GSK's Revolade and InterMune's Esbriet

21-03-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence today (March 21) issued two…

BiotechnologyEsbrietEuropeGlaxoSmithKlineImmunologicalsInterMunePharmaceuticalPricingRegulationRespiratory and PulmonaryRevolade

Ares Life Sciences to acquire Albion Medical and its GREER Laboratories unit

08-03-2013

Ares Life Sciences says it has signed a definitive agreement to acquire 100% of the share capital of…

Albion MedicalAres Life SciencesGREER LaboratoriesImmunologicalsMergers & AcquisitionsOralairPharmaceuticalRespiratory and PulmonaryStallergenes

Novartis/Vectura's QVA149 is filed as a treatment for COPD in Europe; Certican EU approval

26-10-2012

The UK's Vectura Group (LSE: VEC) confirmed that its partner, Swiss drug giant Novartis (NOVN: VX) has…

CerticanEuropeFinancialImmunologicalsNovartisPharmaceuticalQVA149RegulationResearchRespiratory and PulmonaryVectura

ALK Abello partner Torii progresses Japanese development of Mitizax

01-08-2012

Denmark-based allergy specialist ALK Abello (ALKB: DC) revealed yesterday that its strategic partner,…

ALK AbelloImmunologicalsMitizaxPharmaceuticalResearchRespiratory and PulmonaryTorii Pharma

Ablynx extends Nanobody deal with Boehringer

21-03-2012

Belgian drug developer Ablynx (Euronext Brussels: ABLX) yesterday announced a two-year extension of the…

AblynxBiotechnologyBoehringer IngelheimImmunologicalsLicensingOncologyPharmaceuticalRespiratory and Pulmonary

Back to top